BR112014012460A2 - proteínas recombinantes e seus usos terapêuticos - Google Patents

proteínas recombinantes e seus usos terapêuticos

Info

Publication number
BR112014012460A2
BR112014012460A2 BR112014012460A BR112014012460A BR112014012460A2 BR 112014012460 A2 BR112014012460 A2 BR 112014012460A2 BR 112014012460 A BR112014012460 A BR 112014012460A BR 112014012460 A BR112014012460 A BR 112014012460A BR 112014012460 A2 BR112014012460 A2 BR 112014012460A2
Authority
BR
Brazil
Prior art keywords
therapeutic uses
recombinant proteins
sequence
epitopes
receptors
Prior art date
Application number
BR112014012460A
Other languages
English (en)
Other versions
BR112014012460B1 (pt
Inventor
D'hondt Erik
Alan Charlton Keith
Original Assignee
Bioven 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioven 3 Ltd filed Critical Bioven 3 Ltd
Publication of BR112014012460A2 publication Critical patent/BR112014012460A2/pt
Publication of BR112014012460B1 publication Critical patent/BR112014012460B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/4753Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/50Fibroblast growth factor [FGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/65Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/64Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645Dendrimers; Multiple antigen peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

resumo patente de invenção: "proteínas recombinantes e seus usos terapêuticos". a presente invenção refere-se a uma proteína recombinante que expressa um ou mais fatores de crescimento humanos, antígenos de tumor, e/ou seus receptores ou epítopos ou dentro de uma expressão imunogênica que cria uma proteína recombinante em que um ou mais epítopos são apresentados na superfície da sequência em sua configuração natural. a(s) sequência(s) de fatores de crescimento, antígenos de tumor e/ou receptores podem ser expressas dentro da sequência de codificação em posições internas apropriadas ou nos terminais como expressões simples ou como duas ou mais repetições em tandem.
BR112014012460-4A 2011-11-23 2012-11-21 proteínas recombinantes BR112014012460B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161563128P 2011-11-23 2011-11-23
US61/563,128 2011-11-23
US201261654401P 2012-06-01 2012-06-01
US61/654,401 2012-06-01
PCT/IB2012/002876 WO2013076580A2 (en) 2011-11-23 2012-11-21 Recombinant proteins and their therapeutic uses

Publications (2)

Publication Number Publication Date
BR112014012460A2 true BR112014012460A2 (pt) 2017-06-06
BR112014012460B1 BR112014012460B1 (pt) 2021-01-12

Family

ID=47716105

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014012460-4A BR112014012460B1 (pt) 2011-11-23 2012-11-21 proteínas recombinantes

Country Status (22)

Country Link
US (4) US9902760B2 (pt)
EP (2) EP3744343A1 (pt)
JP (4) JP6121436B2 (pt)
KR (2) KR102274211B1 (pt)
CN (3) CN104066447A (pt)
AU (3) AU2012342117B2 (pt)
BR (1) BR112014012460B1 (pt)
CA (1) CA2856255C (pt)
DK (1) DK2782598T3 (pt)
ES (1) ES2812564T3 (pt)
HR (1) HRP20201282T1 (pt)
HU (1) HUE050438T2 (pt)
IL (2) IL232645B (pt)
LT (1) LT2782598T (pt)
MX (1) MX354902B (pt)
MY (2) MY184576A (pt)
PL (1) PL2782598T3 (pt)
PT (1) PT2782598T (pt)
RS (1) RS60782B1 (pt)
RU (2) RU2650574C2 (pt)
SI (1) SI2782598T1 (pt)
WO (1) WO2013076580A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012460B1 (pt) * 2011-11-23 2021-01-12 Bioven 3 Limited proteínas recombinantes
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
CA3070034A1 (en) * 2017-07-18 2019-01-24 In3Bio Ltd. Synthetic proteins and therapeutic uses thereof
CN107880133A (zh) * 2017-11-04 2018-04-06 海南大学 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法
WO2019179361A1 (zh) * 2018-03-21 2019-09-26 傅惠芳 改善括约肌闭锁不全的组合物及其医药组成物与用途
WO2020046982A1 (en) * 2018-08-27 2020-03-05 University Of Virginia Patent Foundation Compositions and methods for preventing and treating virus infection
BR112021026132A2 (pt) * 2019-06-25 2022-02-08 In3Bio Ltd Proteínas sintéticas quiméricas estabilizadas e usos terapêuticos das mesmas
US20220378891A1 (en) 2019-11-07 2022-12-01 In3Bio Ltd. Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
CN116003601A (zh) * 2019-12-05 2023-04-25 启愈生物技术(上海)有限公司 一种抗pd-l1纳米抗体及其用途
WO2021195327A1 (en) * 2020-03-25 2021-09-30 The Regents Of The University Of Colorado, A Body Corporate Bivalent egf fusion toxins
CN113735980A (zh) * 2021-08-23 2021-12-03 中国医学科学院北京协和医院 一种自融合串联蛋白修饰方法及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
CA2137639C (en) * 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
CA2302522C (en) 1997-08-29 2010-08-17 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1030684A4 (en) * 1997-11-14 2004-09-15 Euro Celtique Sa MODIFIED ANTIBODIES WITH IMPROVED CAPACITY TO TRIGGER ANTI-IDIOTYPE RESPONSE
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US7078486B2 (en) * 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US7201905B2 (en) * 2000-03-23 2007-04-10 Greenville Hospital System Bi-functional cancer treatment agents
CU22999A1 (es) 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
EP1390065A2 (en) * 2001-05-14 2004-02-25 Duotol Ab Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
CN1966525A (zh) * 2001-06-13 2007-05-23 根马布股份公司 表皮生长因子受体(egfr)的人单克隆抗体
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
JP2004538331A (ja) 2001-08-17 2004-12-24 ロジャー ウィリアムス ホスピタル インサイチュ免疫法
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
JP2005528107A (ja) * 2002-05-31 2005-09-22 シェジェン ピーティーワイ リミテッド 膜転位置配列由来の自己合体または自己凝集キメラタンパク質
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US8207314B2 (en) * 2003-05-16 2012-06-26 Sanofi Pasteur Limited Tumor antigens for prevention and/or treatment of cancer
US7601341B2 (en) * 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
JP4623625B2 (ja) * 2003-07-24 2011-02-02 株式会社AMBiS ヘテロ型5量体組換えワクチン
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
EP2634252B1 (en) * 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
FR2882654B1 (fr) * 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
CN1686562A (zh) * 2005-03-31 2005-10-26 南京大学 一种转铁蛋白与生物还原剂的结合物及其制备方法
BRPI0707679A2 (pt) * 2006-02-01 2011-05-10 Tjhe Johns Hopkins University conjugado de polipetÍdeo - Àcido nuclÉico para imunoprofilaxia ou imunoterapia para distérbios neoplÁsticos ou infecciosos
ATE473758T1 (de) 2006-04-13 2010-07-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Her-2/neu multipeptidimpfstoff
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
JP2009543071A (ja) * 2006-07-06 2009-12-03 モレキュラー ロジックス,インコーポレイテッド ドミナントネガティブリガンド薬物発見システム
WO2008030988A2 (en) * 2006-09-06 2008-03-13 The Regents Of The University Of California Selectively targeted antimicrobial peptides and the use thereof
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
CN1995064A (zh) * 2006-12-20 2007-07-11 李欣越 增强生物活性的长效重组人红细胞生长因子融合蛋白及方法
CN101679508B (zh) * 2007-02-02 2014-11-05 贝勒研究院 基于靶向抗原至抗原呈递细胞上表达的dcir的疫苗
NZ592859A (en) * 2007-02-02 2012-05-25 Baylor Res Inst Multivariable antigens complexed with targeting humanized monoclonal antibody
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
JP2011187653A (ja) 2010-03-08 2011-09-22 Olympus Corp 防水機器
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
BR112014012460B1 (pt) * 2011-11-23 2021-01-12 Bioven 3 Limited proteínas recombinantes

Also Published As

Publication number Publication date
CN108864261A (zh) 2018-11-23
WO2013076580A3 (en) 2013-08-22
RS60782B1 (sr) 2020-10-30
CA2856255A1 (en) 2013-05-30
JP7470669B2 (ja) 2024-04-18
EP2782598B1 (en) 2020-05-27
RU2018108421A (ru) 2019-02-25
SI2782598T1 (sl) 2020-12-31
LT2782598T (lt) 2020-07-27
RU2018108421A3 (pt) 2021-06-04
US11198716B2 (en) 2021-12-14
CN104066447A (zh) 2014-09-24
IL232645B (en) 2021-01-31
IL232645A0 (en) 2014-06-30
JP6953467B2 (ja) 2021-10-27
AU2012342117B2 (en) 2017-08-31
MX354902B (es) 2018-03-23
KR102274211B1 (ko) 2021-07-09
US20160207972A1 (en) 2016-07-21
JP2022023081A (ja) 2022-02-07
US9902760B2 (en) 2018-02-27
CN108864291A (zh) 2018-11-23
RU2766595C2 (ru) 2022-03-15
EP2782598A2 (en) 2014-10-01
AU2020201297B2 (en) 2022-03-10
US20180162917A1 (en) 2018-06-14
JP2014534258A (ja) 2014-12-18
US20140248302A1 (en) 2014-09-04
DK2782598T3 (da) 2020-08-10
MY184576A (en) 2021-04-06
AU2017268634B2 (en) 2019-11-21
AU2012342117A1 (en) 2013-05-30
US20220153798A1 (en) 2022-05-19
BR112014012460B1 (pt) 2021-01-12
CA2856255C (en) 2021-06-22
PT2782598T (pt) 2020-09-02
MX2014006232A (es) 2015-02-10
AU2012342117A8 (en) 2014-07-03
HUE050438T2 (hu) 2020-12-28
HRP20201282T1 (hr) 2020-11-13
WO2013076580A2 (en) 2013-05-30
IL279676A (en) 2021-03-01
KR102024066B1 (ko) 2019-09-24
AU2017268634A1 (en) 2017-12-21
PL2782598T3 (pl) 2021-03-08
AU2020201297A1 (en) 2020-03-12
JP2017137339A (ja) 2017-08-10
RU2650574C2 (ru) 2018-04-17
ES2812564T3 (es) 2021-03-17
JP6570081B2 (ja) 2019-09-04
JP6121436B2 (ja) 2017-04-26
KR20140108235A (ko) 2014-09-05
JP2019146576A (ja) 2019-09-05
MY188083A (en) 2021-11-16
EP3744343A1 (en) 2020-12-02
RU2014124923A (ru) 2015-12-27
KR20190112161A (ko) 2019-10-02

Similar Documents

Publication Publication Date Title
BR112014012460A2 (pt) proteínas recombinantes e seus usos terapêuticos
CY1123404T1 (el) Αντι-girt αντισωματα
CO7151522A2 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
CU24206B1 (es) Proteínas de fusión que comprenden factor de crecimiento de fibroblastos útil en desórdenes metabólicos
BR112014018630A2 (pt) alvejamento de glicanos de sulfato de condroitina
BR112016020368A2 (pt) proteínas fc multiméricas
MY175708A (en) Dna antibody constructs and method of using same
CR20120404A (es) Proteinas de enlace cd127
WO2015089492A3 (en) Dna antibody constructs and method of using same
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
NZ711567A (en) Antibody formulations
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
WO2014028668A3 (en) Stem cell enhancing therapeutics
PH12015501870B1 (en) Nutritional compositions containing a peptide component with adiponectin stimulating properties and uses thereof
EA201390617A1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики
PE20081687A1 (es) Proteina de fusion
PH12016500708A1 (en) Recombinant glycoproteins and uses thereof
WO2013109190A3 (en) Cho-gmt recombinant protein expression
BR112015023651A2 (pt) expressão aumentada de proteínas de picornavírus
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2012, OBSERVADAS AS CONDICOES LEGAIS.